Cassava Sciences, Inc. (NASDAQ:SAVA) Insider James William Kupiec Sells 4,000 Shares

Cassava Sciences, Inc. (NASDAQ:SAVA) insider James William Kupiec sold 4,000 shares of the business’s stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $3.87, for a total value of $15,480.00. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Cassava Sciences Trading Down 2.8 %

NASDAQ:SAVA traded down $0.09 during mid-day trading on Tuesday, hitting $3.35. The company’s stock had a trading volume of 7,889,972 shares, compared to its average volume of 10,487,342. Cassava Sciences, Inc. has a fifty-two week low of $3.25 and a fifty-two week high of $42.20. The company has a market capitalization of $161.17 million, a price-to-earnings ratio of -2.43 and a beta of -0.86. The stock has a fifty day moving average of $24.48 and a 200-day moving average of $22.66.

Cassava Sciences (NASDAQ:SAVA) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($0.58) earnings per share for the quarter, topping the consensus estimate of ($1.37) by $0.79. During the same quarter in the prior year, the firm earned ($0.61) EPS. On average, equities analysts anticipate that Cassava Sciences, Inc. will post -3.97 earnings per share for the current fiscal year.

Analysts Set New Price Targets

SAVA has been the topic of several research reports. HC Wainwright cut Cassava Sciences from a “buy” rating to a “neutral” rating and set a $116.00 price target on the stock. in a report on Tuesday, November 26th. Rodman & Renshaw restated a “buy” rating and set a $107.00 price target on shares of Cassava Sciences in a report on Thursday, August 8th.

Institutional Investors Weigh In On Cassava Sciences

A number of hedge funds and other institutional investors have recently made changes to their positions in SAVA. Vanguard Group Inc. increased its stake in Cassava Sciences by 1.4% in the 1st quarter. Vanguard Group Inc. now owns 2,356,480 shares of the company’s stock valued at $47,813,000 after buying an additional 31,854 shares during the last quarter. CANADA LIFE ASSURANCE Co boosted its holdings in shares of Cassava Sciences by 146.7% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 9,408 shares of the company’s stock worth $191,000 after buying an additional 5,594 shares during the period. Price T Rowe Associates Inc. MD raised its stake in Cassava Sciences by 4.9% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 31,327 shares of the company’s stock worth $636,000 after purchasing an additional 1,456 shares in the last quarter. Brookstone Capital Management raised its stake in Cassava Sciences by 6.0% in the 2nd quarter. Brookstone Capital Management now owns 17,753 shares of the company’s stock worth $219,000 after purchasing an additional 1,000 shares in the last quarter. Finally, Essex LLC raised its stake in Cassava Sciences by 9.2% in the 2nd quarter. Essex LLC now owns 55,318 shares of the company’s stock worth $683,000 after purchasing an additional 4,644 shares in the last quarter. 38.05% of the stock is currently owned by institutional investors and hedge funds.

Cassava Sciences Company Profile

Cassava Sciences, Inc, a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease.